B Bodaghi, G Gendron, B Wechsler, C Terrada … - British Journal of Ophthalmology, 2007 - bjo.bmj.com Results: 45 patients were included. Median age was 32.3 years (range 8–58) and
sex ratio (F/M) was 0.66. Uveitis was associated with Behçet's disease in 23
cases (51.1%) and with other entities in 22 cases (48.9%). Median duration ... Cited by 36 - Related articles - BL Direct - All 4 versions
CME Deuter, I Koetter, I Guenaydin, N … - Retina, 2006 - pdfs.journals.lww.com From the Departments of *Ophthalmology I and †Internal Med- icine II,
University of Tuebingen, Germany. The authors have no proprietary interest. This
article contains information regarding off-label use of interferon alfa-2a. ... Cited by 21 - Related articles - BL Direct - All 3 versions
I Tugal-Tutkun, E Güney-Tefekli, M … - Graefe's Archive for Clinical and Experimental …, 2006 - Springer Page 1. Graefe's Arch Clin Exp Ophthalmol (2006) 244: 1692–1695 SHORT
COMMUNICATION DOI 10.1007/s00417-006-0346-y Ilknur Tugal-Tutkun ... Cited by 31 - Related articles - BL Direct - All 3 versions
J Plskova, K Greiner, JV Forrester - American Journal of Ophthalmology, 2007 - Elsevier The mean observation period was 11 months (range, one to 29 months). A positive
clinical response was observed in 83% of patients. Median visual acuity improved
from 0.54 to 0.2 (logarithm of the minimum angle of resolution units; P < ... Cited by 15 - Related articles - All 12 versions
AM Abu El-Asrar, EB Abboud, H Aldibhi, A Al- … - International Ophthalmology, 2005 - Springer Abstract Purpose To evaluate the long-term safety and efficacy of infliximab
therapy for refractory uve- itis associated with Behçet's disease (BD). Methods
We prospectively enrolled six patients who failed to respond to ... Cited by 22 - Related articles - BL Direct - All 3 versions
G Sobaci, Z Bayraktar, A Bayer - Ocular Immunology and Inflammation, 2005 - informahealthcare.com Purpose: To describe the management and long-term outcome of patients with
serpiginous choroiditis (SPC) treated with interferon (IFN) alpha-2a. Design:
Prospective, non-comparative case series. Participants: Five patients (8 ... Cited by 15 - Related articles - All 5 versions
- ►nih.gov RR Buggage, G Levy-Clarke, HN Sen, R Ursea … - Ocular immunology and inflammation, 2007 - informahealthcare.com Purpose: To investigate the safety and efficacy of daclizumab (Zenapax,
humanized anti-Tac, HAT) in controlling the ocular manifestations of Behçet's
disease. Design: Randomized, placebo-controlled, double-masked clinical ... Cited by 17 - Related articles - BL Direct - All 6 versions
- ►oxfordjournals.org L Niccoli, C Nannini, M Benucci, D Chindamo, E … - Rheumatology, 2007 - Br Soc Rheumatology 2nd Division of Internal Medicine, Rheumatology Unit, 1 Division of
Ophthalmology, Hospital of Prato, 2 Rheumatology Unit of Nuovo Ospedale S.
Giovanni di Dio, Firenze, 3 Division of Rheumatology, Hospital of Reggio ... Cited by 22 - Related articles - All 7 versions
B Wechsler, B Bodaghi, DL Thi Huong, C … - Ocular Immunology and Inflammation, 2000 - informahealthcare.com Correspondence and reprint requests to: B. Wechsler Department of Internal
Medicine Pitié-Salpêtrière Hospital 47 bld de l'Hôpital 75651 Paris Cedex 13
France Tel: 33 1 42178021 Fax: 33 1 42178032 e-mail: ... Cited by 64 - Related articles - BL Direct - All 4 versions
B Mushtaq, T Saeed, RD Situnayake, PI … - Eye (London, England), 2007 - ncbi.nlm.nih.gov AIMS: To describe the clinical outcome of three patients with Behçet's disease
maintained on infliximab who were switched to adalimumab therapy. METHODS: Case
note review. Main outcome measure was recurrence of uveitis. RESULTS: All ... Cited by 38 - Related articles - BL Direct - All 4 versions
